Cat. No.: HY-101842

ND-646

14 Cited Publications

Avis client

Based on 14 publication(s) in Google Scholar

ND-646 is an orally bioavailable and steric inhibitor of acetyl-CoA carboxylase (ACC) with IC₅₀s of 3.5 nM and 4.1 nM for recombinant hACC1 and hACC2, respectively.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.13%
CAS No.: 1434639-57-2
Formule: C₂₈H₃₂N₄O₇S
Masse moléculaire:568.64

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

ND-646 Chemical Structure

CAS No.: 1434639-57-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (14)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

ND-646 is an orally bioavailable and steric inhibitor of acetyl-CoA carboxylase (ACC) with IC₅₀s of 3.5 nM and 4.1 nM for recombinant hACC1 and hACC2, respectively.

IC₅₀ & Target

IC50: 3.5 nM (hACC1), 4.1 nM (hACC2)^[1]

In Vitro

ND-646 inhibits both ACC1 and ACC2 and therefore precludes the ability of ACC2 to compensate for ACC1 inhibition. ND-646 inhibits dimerization of recombinant human ACC2 BC domain (hACC2-BC) under native conditions; hACC2-BC migrates as a dimer in its absence and a monomer in its presence. In cell free systems, ND-646 inhibits enzymatic activity of recombinant human ACC1 (hACC1) with an IC₅₀ of 3.5 nM and recombinant human ACC2 (hACC2) with an IC₅₀ of 4.1 nM^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

To explore the impact of chronic ND-646 treatment on NSCLC tumor growth and to determine the efficacy of twice-daily dosing, athymic nude mice bearing established A549 subcutaneous tumors are treated orally with either vehicle twice daily (BID), 25 mg/kg ND-646 once daily (QD), 25 mg/kg ND-646 BID or 50 mg/kg ND-646 QD for 31 days. ND-646 at 25 mg/kg QD is ineffective at inhibiting tumor growth. However, ND-646 administered at 25 mg/kg BID or 50 mg/kg QD significantly inhibits subcutaneous A549 tumor growth. ND-646 is well tolerated throughout the treatment period, with no significant weight loss occurring after chronic ND-646 dosing, suggesting that the maximum tolerated dose (MTD) has not been reached. Mice are sacrificed at 1 hr post final dose and tissues are either prepared for immunohistochemistry (IHC) or immunoblot analysis. Tumors treated with all doses of ND-646 have lost detection of P-ACC at 1 hr, demonstrating effective tumor penetration and acute ACC inhibition by ND-646. Notably, only at the doses of ND-646 that lead to significant tumor growth inhibition (25 mg/kg BID and 50 mg/kg QD) is significant elevation of P-EIF2α^S51 expression observed in tumor lysates^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 1434639-57-2
Appearance Solid
Masse moléculaire 568.64
Formule C₂₈H₃₂N₄O₇S
Color White to off-white
SMILES

O=C(N)C(C)(C)N(C(N(C[C@@H](C1=CC=CC=C1OC)OC2CCOCC2)C3=C4C(C)=C(C5=NC=CO5)S3)=O)C4=O
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (14)

All In Vivo Efficacy StudyCell Imaging/StainingBio/Physico-chemical AssayWBIF

Sort by:

Journal Impact Factor

Science

Superstable lipid vacuoles endow cartilage with its shape and biomechanics. [Abstract]

2025 Jan 10;387(6730):eads9960. PMID: 39787221

ND-646 purchased from MedChemExpress. Usage Cited in: Science. 2025 Jan 10;387(6730):eads9960. [Abstract]

Ears become smaller in mice topically treated with de novo lipogenesis inhibitors PF-05175157 (PF), ND-646 (ND) and C75 as compared to DMSO control.
Cell Metab

Acetyl-CoA carboxylase obstructs CD8+ T cell lipid utilization in the tumor microenvironment. [Abstract]

2024 May 7;36(5):969-983.e10. PMID: 38490211
Cancer Discov

Changes in Aged Fibroblast Lipid Metabolism Induce Age-Dependent Melanoma Cell Resistance to Targeted Therapy via the Fatty Acid Transporter FATP2. [Abstract]

2020 Sep;10(9):1282-1295. PMID: 32499221

ND-646 purchased from MedChemExpress. Usage Cited in: Cancer Discov. 2020 Sep;10(9):1282-1295. [Abstract]

Melanoma cells treated with 4nM ND646 in the presence of young and aged fibroblast conditioned media for 48 hrs followed by Trypan blue exclusion analysis.
Redox Biol

IL-10 protects against OPC ferroptosis by regulating lipid reactive oxygen species levels post stroke. [Abstract]

2024 Feb:69:102982. PMID: 38070317

ND-646 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Feb:69:102982. [Abstract]

We treated OPCs with ND-646 (0-10 nM), the specific inhibitor of ACC, and found it protected against hemin-induced lipid ROS accumulation and ferroptosis dose-dependently as IL-10 and DLK1 did.

ND-646 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Feb:69:102982. [Abstract]

Hemin increased the contents of triacylglycerol (TAG) and phosphatidylcholine (PC) in OPCs, while hemin plus IL-10 or ND-646 treatment significantly reduced the contents of TAG, phosphatidylglycerol (PG), phosphatidylethanolamine (PE), and PC.

ND-646 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Feb:69:102982. [Abstract]

IL-10 and ND-646 treatment both decreased these metabolites levels.

ND-646 purchased from MedChemExpress. Usage Cited in: Redox Biol. 2024 Feb:69:102982. [Abstract]

Both IL-10 and ND-646 treatment rescued cognitive impairment of WT ICH mice, while AG490 abolished IL-10 effects significantly.
J Neuroinflammation

Metformin inhibits intracranial aneurysm formation and progression by regulating vascular smooth muscle cell phenotype switching via the AMPK/ACC pathway. [Abstract]

2020 Jun 16;17(1):191. PMID: 32546267

ND-646 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2020 Jun 16;17(1):191. [Abstract]

Western blot analysis of total AMPK, p-AMPK, ACC, p-ACC, α-SMA, SM22α, and GAPDH expression in VSMCs treated as indicated.

ND-646 purchased from MedChemExpress. Usage Cited in: J Neuroinflammation. 2020 Jun 16;17(1):191. [Abstract]

The level of p-ACC is decreased by exposure to ND-646, with no observable difference in p-AMPK expression. qRT-PCR analysis revealed that α-SMA and SM22α are downregulated in the presence of ND-646, which is corroborated by immunofluorescence labeling.
Phytomedicine

Unveiling plumbagin as a novel metabolic modulator to suppress ACC1-mediated de novo lipogenesis in non-small cell lung cancer. [Abstract]

2025 Nov 25:148:157438. PMID: 41187651
Clin Cancer Res

Targeting Acetyl-CoA Carboxylase Suppresses De Novo Lipogenesis and Tumor Cell Growth in Multiple Myeloma. [Abstract]

2025 May 15;31(10):1975-1987. PMID: 40053701
Int J Mol Sci

Augmented Global Protein Acetylation Diminishes Cell Growth and Migration of Cholangiocarcinoma Cells. [Abstract]

2024 Sep 22;25(18):10170. PMID: 39337655
J Biol Chem

Hydrogen sulfide stimulates lipid biogenesis from glutamine that is dependent on the mitochondrial NAD(P)H pool. [Abstract]

2021 Aug;297(2):100950. PMID: 34252456
bioRxiv

2026 Feb 1.
bioRxiv

2023 Nov 17.
Elife

A powerful drug combination strategy targeting glutamine addiction for the treatment of human liver cancer. [Abstract]

2020 Oct 5;9:e56749. PMID: 33016874
University of the Sciences in Philadelphia

2020 Jul.
bioRxiv

2020 Jun.

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (175.86 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.7586 mL

8.7929 mL

17.5858 mL

5 mM

0.3517 mL

1.7586 mL

3.5172 mL

10 mM

0.1759 mL

0.8793 mL

1.7586 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Cell Assay^[1]

A549, H460, H157 and H1355 cells are tested for Mycoplasma and are deemed negative. Cells are grown in DMEM plus 10% fetal bovine serum. ACC1-KO clones are maintained in 10% FBS+addition of 200 μM palmitate every 3 days. For proliferation assays via cell counts, cells are plated into 24 well plates in triplicate at 2^E4 cells/well and the following day treated with either DMSO vehicle or ND-608 or ND-646. Cell counts are recorded at days 1, 3, 5 and 7-post treatment. For delipidated media, cells are first seeded in media containing regular 10% FBS and the following day are switched into media containing 20% delipidated FBS upon treatment. Viability assays are performed using either a WST-1 viability assay or Cyquant in 96 well culture plates^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[1]

Mice^[1]
Subcutaneous tumor studies: For ACC1-KO studies, 8 week old athymic female nude mice are injected subcutaneously into the hind flanks with 2^E6 cells of either WT or ACC1-KO luciferase expressing clones in a volume of 200 μL and imaged by BLI 20 mins after injection. Mice undergo BLI weekly for a period of 42 days (A549) and 49 days (H157), then mice are sacrificed and tumors are dissected and weighed. For ND-646 subcutaneous studies, female athymic nude mice are injected subcutaneously into the hind flanks with 5^E6 A549 cells. Tumor growth is measured daily using digital calipers and volumes are calculated. Tumor prevention studies begin at 11 days post tumor cell injection. Mice are randomized into their treatment groups based on similar average tumor volumes. The average tumor volume at the initiation of treatment is 40 mm³. Mice are dosed orally (Per OS) once or twice a day with either a vehicle solution or ND-646 at either 25 mg/kg or 50 mg/kg (0.9% NaCl, 1% Tween 80, 0.5% methylcellulose). At the end of the study, mice are euthanized 1hr post final dose.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (286 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Svensson RU, et al. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models. Nat Med. 2016 Oct;22(10):1108-1119. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.7586 mL	8.7929 mL	17.5858 mL	43.9645 mL
	5 mM	0.3517 mL	1.7586 mL	3.5172 mL	8.7929 mL
	10 mM	0.1759 mL	0.8793 mL	1.7586 mL	4.3965 mL
	15 mM	0.1172 mL	0.5862 mL	1.1724 mL	2.9310 mL
	20 mM	0.0879 mL	0.4396 mL	0.8793 mL	2.1982 mL
	25 mM	0.0703 mL	0.3517 mL	0.7034 mL	1.7586 mL
	30 mM	0.0586 mL	0.2931 mL	0.5862 mL	1.4655 mL
	40 mM	0.0440 mL	0.2198 mL	0.4396 mL	1.0991 mL
	50 mM	0.0352 mL	0.1759 mL	0.3517 mL	0.8793 mL
	60 mM	0.0293 mL	0.1465 mL	0.2931 mL	0.7327 mL
	80 mM	0.0220 mL	0.1099 mL	0.2198 mL	0.5496 mL
	100 mM	0.0176 mL	0.0879 mL	0.1759 mL	0.4396 mL

Keywords

ND-646

14 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

ND-646

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Endoplasmic Reticulum Stress Compound Library

Anti-Lung Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) ND-646

Activité biologique

Chemical Information

Publications (14)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

ND-646

Immunology/Inflammation Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Endoplasmic Reticulum Stress Compound Library

Anti-Lung Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Obesity Compound Library

Lipid Metabolism Compound Library

Heterocyclic Compound Library

Metabolic Enzyme Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Publications Citing Use of MedChemExpress (MCE) ND-646

Activité biologique

Chemical Information

Publications (14)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

ND-646 Related Classifications

HY-101842 Related Classifications